Lord Abbett & CO. LLC Has $126.52 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Lord Abbett & CO. LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 175.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 187,009 shares of the company’s stock after buying an additional 119,182 shares during the quarter. Lord Abbett & CO. LLC owned about 0.23% of IDEXX Laboratories worth $126,517,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Up 0.5%

Shares of NASDAQ IDXX opened at $560.88 on Friday. The firm has a market cap of $44.24 billion, a PE ratio of 41.30, a P/E/G ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company’s fifty day simple moving average is $563.06 and its 200 day simple moving average is $627.69. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.